Gaurav Aggarwal - 25 Aug 2025 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Reporting relationship: Director
Issuer ticker: UNCY
Reported as of: 25 Aug 2025
Net transaction value: -$3,199,210
SEC form: 4
Accepted by SEC: 26 Aug 2025, 17:06:30 UTC
Prior SEC filing: 30 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Gaurav Aggarwal

Key filing fact

Gaurav Aggarwal filed Form 4 for Unicycive Therapeutics, Inc. (UNCY) on 26 Aug 2025.

Key facts

This page summarizes Gaurav Aggarwal's Form 4 filing for Unicycive Therapeutics, Inc. (UNCY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Aug 2025, 17:06.

Change

Previous filing in this sequence was filed on 30 Jul 2025.
Current net transaction value: -$3,199,210.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001551965 Primary reporting owner

Aggarwal Gaurav

Relationship: Director
Address: C/O UNICYCIVE THERAPEUTICS, INC., 4300 EL CAMINO REAL SUITE 210, LOS ALTOS
Signature: /s/ Gaurav Aggarwal
Signature date: 26 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UNCY transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +652,900
Change %: +57%
Price
Shares after: 1,789,915
Date: 25 Aug 2025
Ownership: By Vivo Opportunity Fund Holdings L.P.
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UNCY transaction Derivative

Series A-2 Prime Preferred Stock

Disposed to Issuer

Transaction value: $3,199,210
Shares: -3,199
Change %: -100%
Price: $1000.00
Shares after: 0
Date: 25 Aug 2025
Ownership: By Vivo Opportunity Fund Holdings L.P.
Underlying class: Common Stock
Underlying amount: 652,900
Exercise price: $4.90
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each share of Series A-2 Prime Preferred Stock is convertible into a number of shares of Common Stock obtained by dividing the Original Per Share Price ($1,000) by $4.90, subject to blocking provisions. Capitalized terms used but not defined herein shall have the meanings set forth in the Amended and Restated Certificate of Designation of Series A Convertible Voting Preferred Stock, filed as an exhibit to the Issuer's Periodic Report on Form 8-K on March 14, 2024.

Footnote F2

Vivo Opportunity Fund Holdings, L.P. is the record holder of the securities. The Reporting Person is a managing member of Vivo Opportunity, LLC, which is the general partner of Vivo Opportunity Fund Holdings, L.P. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Footnote F3

The shares of Series A-2 Prime Preferred Stock were issued on March 14, 2024 and do not have an expiration date.